Pediatr Nephrol (2015) 30:1861–1871 DOI 10.1007/s00467-015-3089-3

ORIGINAL ARTICLE

Towards a biomarker panel for the assessment of AKI in children receiving intensive care

James McCaffrey^{1,5} • Beatrice Coupes² • Chris Chaloner⁴ • Nicholas J. A. Webb^{1,5} • Rachael Barber³ • Rachel Lennon^{1,5}

Received: 13 October 2014 / Revised: 2 March 2015 / Accepted: 6 March 2015 / Published online: 15 April 2015 © The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract

Background Critically ill children and neonates are at high risk of developing acute kidney injury (AKI). AKI is associated with short- and long-term renal impairment and increased mortality. Current methods of diagnosing AKI rely on measurements of serum creatinine, which is a late and insensitive marker. Few studies to date have assessed AKI biomarkers in a heterogeneous patient cohort.

Methods We conducted a prospective feasibility study in a paediatric intensive care setting over a 6-month period to describe the relationship between AKI (defined according to pRIFLE criteria) and new AKI biomarkers.

Results In total, 49 patients between the ages of 16 days and 15 years were recruited for measurement of plasma cystatin C (Cys-C) and neutrophil gelatinase-associated lipocalin

Electronic supplementary material The online version of this article (doi:10.1007/s00467-015-3089-3) contains supplementary material, which is available to authorized users.

Rachel Lennon Rachel.Lennon@manchester.ac.uk

- ¹ Department of Paediatric Nephrology, Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust (CMFT), Manchester Academic Health Science Centre, Manchester, UK
- ² Department of Renal Medicine, CMFT, Manchester Academic Health Science Centre, Manchester, UK
- ³ Paediatric Intensive Care Unit, CMFT, Manchester Academic Health Science Centre, Manchester, UK
- ⁴ Department of Biochemistry, CMFT, Manchester Academic Health Science Centre, Manchester, UK
- ⁵ Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK

(pNGAL) concentrations, as well as for urinary kidney injury molecule-1 (KIM-1) and urinary NGAL (uNGAL) concentrations. Almost one-half (49 %) of the patient cohort experienced an AKI episode, and Cys-C and pNGAL were the strongest candidates for the detection of AKI. Our data suggest that the widely used estimated baseline creatinine clearance value of 120 mL/min/1.73 m² underestimates actual baseline function in patients admitted to paediatric intensive care units.

Conclusions This investigation demonstrates the feasibility of new AKI biomarker testing in a mixed patient cohort and provides novel biomarker profiling for further evaluation.

Keywords Acute kidney injury · Paediatric intensive care unit · Biomarkers · Cystatin C · Neutrophil gelatinase-associated lipocalin · Kidney injury molecule-1

Introduction

Acute kidney injury (AKI) is a serious condition characterized by the sudden onset of renal dysfunction, leading to impaired control of acid–base, electrolyte and fluid balance. AKI is a common problem in children admitted to the paediatric intensive care unit (PICU). The incidence of AKI following admission to PICU varies from 4.5 to 82 %, with higher incidence in children requiring invasive mechanical ventilation and/or vasoactive medications [1–4]. The most comprehensive longitudinal paediatric follow-up study currently available was limited by follow-up rates of less than 50 %, but it reported overall 3- to 5-year post-AKI patient survival of only 57 %, with 9 % of surviving children developing end-stage renal disease by 5 years [1].

Despite the clinical significance of AKI, current diagnosis and treatment strategies remain suboptimal. Diagnosis of AKI relies on serum measurements of muscle-derived creatinine. which is efficiently excreted by the healthy kidney. However, baseline serum creatinine (SCr) excretion shows wide variation associated with age, sex, muscle mass and other interindividual variability [2]. In addition, SCr levels only rise above baseline when 25-50 % of renal function has been lost [3], and there may be a temporal dissociation between rises in SCr and true renal filtration [5]. The ability to diagnose AKI earlier in the disease course would allow a more timely instigation of interventions to prevent secondary damage (such as dose-adjustment or elimination/avoidance of nephrotoxic medicines, avoidance of intravenous contrast agents and appropriate fluid management) and, where applicable, earlier initiation of renal replacement therapy. Additionally, current evaluation of novel therapeutic strategies is hampered by treatment initiation only commencing after significant renal damage has occurred [6].

AKI in paediatric patients is classified using the criteria of the paediatric RIFLE classification system for AKI [pRIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease)] [4]. The pRIFLE classification/staging system stratifies AKI based on urine output and changes in estimated creatinine clearance (eCCl) rather than the absolute SCr value. In addition to the development of AKI classification systems, there has been a long-standing search for novel biomarkers to enable earlier detection of AKI. A number of candidate biomarkers were identified following the discovery and identification of renal genes that are rapidly upregulated following a period of renal ischaemia [7, 8]. These include human neutrophil gelatinaseassociated lipocalin (NGAL) [9–12], cystatin-C (Cys-C) [13, 14] and kidney injury molecule-1 (KIM-1) [12, 15].

AKI biomarker studies in the paediatric population have to date focused on selected groups of patients, such as children undergoing cardiopulmonary bypass procedures [13, 16] or following the onset of haemolytic uraemic syndrome [10], and a number of studies have exclusively focussed on neonates [11, 14, 15]. Of those studies that have examined more general admissions, data are only provided for urinary biomarkers [12, 17, 18] or exclusively in the neonatal period [14]. A recent study involving 214 children admitted to PICUs with sepsis showed that a combination of three plasma AKI biomarkers and clinical risk stratification strongly predicts the development of severe renal injury in children with sepsis [19].

Here we present data from a feasibility study, which is the first to examine both urinary and plasma biomarkers at multiple time points in a general PICU population. The aims of our study were: (1) to identify biomarkers that differentiate patients with and without AKI in a heterogeneous paediatric cohort; (2) to examine whether biomarkers provide an earlier warning of AKI than pRIFLE criteria; (3) to investigate whether a combination of biomarkers improves the identification of AKI.

Methods

Study design and participants

The study group was a prospective cohort of patients admitted either electively or as an emergency to the PICU at the Royal Manchester Children's Hospital (RMCH) between December 2011 and June 2012. Subjects younger than 16 years of age admitted to the PICU who required the insertion of a central venous or peripheral arterial line and urinary catheter as part of their routine clinical care were eligible for recruitment. Patients whose parents or guardians did not consent or those with stage 4 or 5 chronic kidney disease or who were dialysis dependent prior to their PICU admission were excluded; no patients who had undergone previous renal transplantation were recruited. The acceptability of using deferred consent in this population was explored.

Ethical approval and consent

The study received ethical approval from the National Research Ethics Committee (ref: 11/NW/0553) and was sponsored by Central Manchester University Hospitals NHS Foundation Trust (ref: R01708). Written consent was obtained for every participant from their parents or guardians. Special approval was granted for consent to be obtained retrospectively up to 48 h after admission, at which point sample collection had already commenced.

Measurement of biomarkers

Blood and urine samples were collected twice daily from the time of PICU admission for a maximum period of 7 days. Samples were stored at 4 °C post-collection for a maximum of 16 h before transfer to the laboratory for processing. Stability of our proposed biomarkers has previously been demonstrated over this time period [20, 21]. Laboratory processing of blood samples involved centrifugation at 2000 rpm for 10 min to separate the plasma, which was aliquoted and stored at -80 °C. Laboratory processing of urine samples involved centrifugation at 2000 rpm for 5 min, followed by aliquoting of the samples and storage at -80 °C. All samples were batched for analysis of biomarkers.

NGAL and KIM-1 were measured by colourimetric immunoassay using commercially available reagents following the manufacturer's guidelines. Plasma NGAL (pNGAL) and urine NGAL (uNGAL) were assayed using the R&D Systems (Oxford, UK) duoset DY1757. R&D immunoassay reagents (DLCN20) have been reported to demonstrate satisfactory performance for all parameters tested in a rigorous evaluation of NGAL measurement [22]. Urine KIM-1 (uKIM-1) was assayed using the R&D Systems duoset DY1750. A detailed evaluation of this assay for uKIM-1 demonstrated reliability in a standard clinical research setting [21]. Assay plates were read on a SPECTRAmax 340PC (Molecular Devices, Sunnyvale, CA). Sample concentrations in all assays were calculated from a 4-parameter standard curve (SOFTmax PRO v4 software; Molecular Devices). In both assays an intra-assay coefficient of variation (CV) of <10 % was confirmed in our hands, and an internal standard included on each assay plate confirmed an inter-assay CV of <20 % throughout the duration of the study. Biomarker concentrations in urine were corrected for Cr concentration [measured by a modified version of the 555 creatinine assay kit (Sigma Aldrich, St. Louis, MO), using the Jaffe reaction) and expressed as units/mg Cr.

Plasma Cys-C concentration was measured using a particle-enhanced immunoturbidimetric assay (Tina-quant; Roche Diagnostics, Mannheim, Germany) on a Roche Cobas 6000 modular instrument (Roche Diagnostics) using the manufacturer's assay configuration and settings. Calibrators (CfAS) and control materials were used as supplied with the Roche kits. Cys-C concentration was measured in heparinized plasma samples after separation from the cells by centrifugation and transfer to a secondary analytical cup. The betweenbatch coefficients of variation established from daily repeated measures of control material were 1.37 % at 1.27 mg/L and 1.21 % at 4.49 mg/L (n=26 each). The manufacturer's reported measuring range is 0.4–8.0 mg/L.

Definition of AKI

Patients were classified using the pRIFLE criteria for AKI which assess a combination of changes in eCCl from baseline eCCl and absolute urine output values [4]. The pRIFLE Risk ^(B) stage is defined by a 25 % decrease in eCCl±urine output of <0.5 mL/kg/h for 8 h; the pRIFLE Injury (I) stage is defined by a 50 % decrease in eCCl±urine output of <0.5 mL/kg/h for 16 h; the pRIFLE Failure (F) stage is defined by a 75 % decrease in eCCl or an eCCl of <35 mL/min/1.73 m²±urine output of <0.3 mL/kg/h for 24 hr or anuria for 12 h.

eCCl was calculated in the same way as the estimated glomerular filtration rate in children, i.e. using the Schwartz formula calculation with a k coefficient of 36.5, in keeping with our local practice [23]. Baseline kidney function was defined as the lowest known SCr value in the 3 months prior to hospital admission. Patients with no known prior SCr values available were assigned a baseline eCCl of 120 mL/min/1.73 m² [12, 19]. As shown in Fig. 1 (overview of patient recruitment), patients were assigned to groups on the basis of the most severe pRIFLE stratum they reached during PICU admission (pRIFLEmax) on either SCr (pRIFLE_{SCr}) or urine output (pRIFLE_{UOP}) criteria. For subsequent analyses, biomarker values were allocated to

pRIFLE strata in a time-specific manner. For example, biomarker values in the 'pRIFLE R' group included any biomarker reading at any time, for any patient, for which that patient at that time was reaching the inclusion criteria for pRIFLE R. Each individual biomarker reading was only included in a single pRIFLE stratum, an approach which avoided pre-insult and post-recovery biomarker values confounding the results.

Statistical analysis

The correlations between biomarker levels and SCr were analysed by calculating a Spearman non-parametric correlation coefficient (r). SCr levels were first normalized for patient height using the Schwartz equation (effectively calculating an eCCl). The correlation coefficient ranges from -1 to +1. A correlation coefficient of 0 signifies that there is no correlation between biomarker levels, while a value of -1 or +1 signifies perfect correlation [24]. Biomarker levels were also compared between different pRIFLE strata. Continuous variables were assessed by non-parametric testing (Mann-Whitney U test for two groups and the Kruskal-Wallis test followed by Dunn's multiple comparison test for three groups or more). We determined receiver operator characteristic (ROC) curves and calculated the areas under the curves (AUCs) for the four biomarkers analysed in this study. ROC curves were compared using the method of Hanley and McNeil [25]. An AUC of 0.5 is no better than expected by chance, whereas a value of 1.0 signifies a perfect biomarker. All analyses were performed using GraphPad Prism version 5.04 for Windows (GraphPad Software, San Diego CA).

Results

Cohort characteristics and incidence of AKI

Over the study period, there were 494 admissions to the PICU (Fig. 1a), from which a total of 49 patients were recruited into the study. The most common cause for study ineligibility was the absence of a urinary catheter (219/445, 49.2 %) or central venous or peripheral arterial line (168/445, 37.8 %); the presence of a urinary catheter and central venous or peripheral arterial line (168/445, 37.8 %); the presence of a urinary catheter and central venous or peripheral arterial line were necessary for sample collection. This inclusion requirement led to recruitment of a cohort of particularly unwell PICU patients. Summary characteristics are presented in Table 1. Of the 49 patients, 26 (53 %) were female, and 25 (58.1 %) were White British; the median age of the entire patient cohort was 3 (range 0.04-15) years. The most common reason for admission was pneumonia (12/49, 24.5 %) and sepsis (12/49, 24.5 %). Ventilation was required by 43/49

Fig. 1 Patient recruitment and acute kidney injury (*AKI*) classification. **a** Total patient cohort, **b** patients admitted with diagnosis other than sepsis or pneumonia. *pRIFLE* Pediatric RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease) classification system for AKI, *PICU* paediatric intensive care unit



(88 %) patients. The mortality rate was 5/49 (10.2 %). Of the 49 patients, four (8.2 %) were admitted electively, none of whom experienced an AKI episode, and 24 (49.0 %) experienced an AKI episode during PICU admission. Twelve patients reached pRIFLEmax R, nine patients reached pRIFLEmax F (Fig. 1a).

Baseline creatinine clearance

In previous AKI studies in children, a presumed baseline eCCl (calculated using the Schwartz formula) of 120 mL/min/1.73 m² has been used in the absence of pre-admission SCr readings [12, 19]. In our study, we examined whether an eCCl of 120 mL/min/1.73 m² was representative of baseline renal function in our patient cohort. We obtained pre-admission and pre-discharge SCr values for study subjects to calculate eCCls. Pre-admission SCr values were recorded if available in the 3-month period prior to hospital admission. Pre-discharge SCr values were defined as the final SCr recording prior to hospital discharge, although this may have been affected by muscle loss during the PICU admission. We excluded patients who died prior to

PICU discharge. Only 4/49 (8.2 %) of our patient cohort had pre-admission SCr values, and Fig. 2 shows that the majority of pre-admission (75.0 %) and pre-discharge (68.2 %) eCCl values were above the presumed baseline value of 120 mL/min/1.73 m². These data suggest that the widely used presumed baseline eCCl value of 120 mL/min/ 1.73 m² may underestimate baseline renal function in our patient cohort.

Biomarkers responsive to changes in eCCl

Biomarker profile plots were created for each patient to aid visualization of data, and an example plot from a patient with AKI (pRIFLEmax I) is shown in Fig. 3. This profile demonstrates an increase in Cys-C coincident with falling eCCl and peaks in pNGAL, uNGAL and KIM-1 prior to the decrease in eCCl. A representative set of biomarker plots from a patient not experiencing AKI is provided in Electronic Supplementary Material Fig. 1.

To determine whether eCCl values from all patients correlated with coincident biomarker values, we calculated a Spearman non-parametric correlation coefficient (r)for each biomarker. A significant correlation was

Table 1 Baseline characteristics and clinical details of patient cohort

Age (yans) 3 1-7 0.04-15.00 Sec 5 0 0.04-15.00 Male 25 (3) Male 25 (3) Male 25 (47) 12.9 8.0-28.5 1.9-70.0 Weight (kg) 12.9 8.0-28.5 1.9-70.0 1.9-70.0 Ethnicity 43 available White British 25 (53.) 1.9-70.0 White British 25 (53.) 1.9-70.0 1.9-70.0 1.9-70.0 Palaismi 9 (20.9) 0 0 1.9-70.0 1.9-70.0 Didgrosis at admission Pre- 7.0 1.9-70.0 1.9-70.0 Pressures 5 (10.2) Cardiae ares 1.2 (24.5) 1.9-70.0 1.9-70.0 Stars is admission 12 (24.5) Stars is admission 1.2 (24.5) 1.9-70.0 1.9 <td< th=""><th>Patient baseline and clinical characteristics</th><th>Number (%)</th><th>Median</th><th>Iinterquartile range</th><th>Range</th></td<>	Patient baseline and clinical characteristics	Number (%)	Median	Iinterquartile range	Range
SerFende26(3)Male25(47)Heijdt (an)65.0Viejdt (kg)12.0Sharka25 (38.1)Nate of the series25 (38.1)Oher Mane Macheman25 (38.1)Oher Mane Macheman20.9Joher Mane Macheman20.9Oher Mane Macheman20.9Strakspression12 (24.5)Gardae ares Macheman20.2Gardae ares Macheman20.2Gardae ares Macheman20.2Benegency Surgical46.2)Interna60.1Ohar A internation20.1Ohar A internation20.1Starsen20.1Taman60.3Ohar A internation20.1Ohar A internation20.1Starars A internation20.1Starars A internation20.1Ohar A internation20.1Starars A internation20.1Data1.21Internation20.1Internation20.1Starars A internation20.1Internation20.1Internation20.1Internation20.1Internation20.1Internation20.1Internation <td>Age (years)</td> <td></td> <td>3</td> <td>1–7</td> <td>0.04-15.00</td>	Age (years)		3	1–7	0.04-15.00
Fende26 (3)Male23 (47)Kejút (40)5.0Vejút (40)12.98.0.28.51.9.700Buhoisty43 avalableValka British25 (58.1)Oher White61 (40.0)Paistani9 (20.9)Oher Asin bakground9 (20.9)Oher Sain bakground9 (20.9)Dignovis at advance7.0Dignovis at advance12 (24.5)SIRS Segniskohock12 (24.5)Gardiac arrest5 (10.2)Cardiac arrest16 (20.1)Cardiac arrest16 (20.1)Taman16 (21.1)Other7 (14.3)Pre-extigti illness2 (4.1)Other1 (22.6)Seiznes2 (4.1)Other1 (24.8)Nane16 (25.1)Ventitatel (day)48 (87.7)Seiznes1 (4.3)Other2 (4.3)Other2 (4.3)Other1 (24.8)Ventitatel (day)4 (8.7)Seiznes1 (2.6)Other1 (2.6)Unitate (day)4 (8.7)Indepension1 (2.9)Ventitatel (day)1 (2.9)Filiphet1 (2.9)Filiphet1 (2.9)Filiphet1 (2.9)Filiphet1 (2.9)Filiphet1 (2.9)Filiphet1 (2.9)Filiphet1 (3.1)Filiphet1 (3.1)Filiphet1 (3.1)Filiphet1 (3.1)Filiphet1 (3.1)<	Sex				
Mak23 (47)Hajat (cm)9.074.0-120.044.0-173.0Wajah (kg)12.98.0-28.51.9-70.0Ehniciy35 (8.1)1.28.0-28.51.9-70.0Oher Main25 (8.1)5.01.01.0Oher Main6.10.01.01.01.0Palatarini0 (20.0)1.01.01.0Oher Adan badground3 (7.0)1.01.01.0Diagrassi at admission12.04.5)1.01.01.0Paemonia12.04.5)1.01.01.01.0Electric sampial4.03.01.01.01.01.0Bengency Surgial4.03.01.01.01.0Other0.10.11.01.01.01.01.0National Statemistic2.01.01.01.01.0Other0.10.31.01.01.01.01.0Other1.01.01.01.01.01.0National State2.01.01.01.01.01.0Other1.01.01.01.01.01.01.0National State1.01.01.01.01.01.01.0National State1.0 <t< td=""><td>Female</td><td>26 (53)</td><td></td><td></td><td></td></t<>	Female	26 (53)			
hieght (m)95074.0-12.0044.0-17.30Weight (kg)12.98.0-28.51.9-70.0Edmixity25 (\$3.1)1.91.9Mite British25 (\$3.1)1.91.9Other Mite6 (14.0)1.91.9Other Mite9 (0.9)1.91.9Other Mite0 (20.9)1.91.9Disposis at domains ion1.01.91.9Permonia12 (24.5)1.91.9Strikspissishock1.0 (2.1)1.91.9Cardia area6.10.2)1.91.9Electre sangical4.8.31.91.9Energency Surgical4.8.31.91.9Other7.14.3)1.91.9Seizares2.6.1)1.91.9Other7.14.3)1.91.9Seizares1.6.1)1.91.9Other1.91.91.9Other1.91.91.9Other1.91.91.9Other1.01.91.9Other1.01.91.9Other1.01.91.9Other1.01.91.9Other1.91.91.9Other1.01.91.9Other1.01.91.9Other1.01.91.9Other1.01.91.9Other1.01.91.9Other1.01.91.9Other <t< td=""><td>Male</td><td>23 (47)</td><td></td><td></td><td></td></t<>	Male	23 (47)			
Weight (kg)12.98.0-28.51.9-700Enhuicity43 availableWhite British25 (8.1)Other Mine9 (20.9)Other Asian background9 (20.9)Digensis at durinision12 (24.5)Parumonia12 (24.5)Cardiac arrest5 (10.2)Elective sargical4 (8.2)Elective sargical4 (8.2)Taruma3 (6.1)Sitzense2 (4.1)Other16 (32.6)Sitzense2 (4.1)Other1 (4.3)Secures2 (4.1)Other3 (6.1)Nearomousclar3 (6.1)Nearomousclar3 (6.1)Other1 (24.8)Vernitate (days)4 (8.7)Satzures3 (6.1)Other1 (24.8)Vernitate (days)4 (8.7)Satzures3 (6.1)Unitate (days)4 (8.7)Satzures1 (2.9)Vernitate (days)4 (8.7)Satzures1 (2.9)CVVH1 (2.1)Elective satistical (days)4 (8.7)Satzures1 (2.9)CVVH1 (2.1)Intotac (days)4 (3.7)Pielo (days)1 (2.1)Pielo (days)1 (2.1)Pielo (days)1 (2.1)Pielo (days)1 (2.2)Pielo (days)1 (2.2)Pielo (days)1 (2.2)Pielo (days)1 (2.2)Pielo (days)1 (2.9)Pielo (days)1 (2.9)Pielo (days)1 (2.9)<	Height (cm)		95.0	74.0-120.0	44.0-173.0
Efficiency34 valableWhite British25 (58.1)Oher Also Borksprond6 (14.0)Polkshin0.00.9Oher Also Borksprond3 (70.1Unumnia3 (70.1JRSSespissbok12 (45.1)Cedici arrest6 (10.2)Intrans6 (10.2)Brenzero Strugilation6 (10.2)Foregrest Strugilation6 (10.2)Turuna6 (10.2)Starzerist2 (4.1)Starzerist2 (4.1)Starzerist2 (4.1)Gende7 (14.3)Starzerist3 (1.3)Starzerist3 (1.3)Starzerist3 (1.3)Civiliate (days)6 (1.2)Oher1 (2.4)Gende7 (14.3)Starzerist3 (1.3)Civiliate (days)6 (1.2)Dark1 (2.4)Civiliate (days)6 (1.2)Dark1 (2.4)Civiliate (days)6 (1.2)Dark1 (2.4)Dark1 (2.4)Dark1 (2.4)Civiliate (days)6 (1.2)Dark1 (2.4)Dark1 (2.4)Dark	Weight (kg)		12.9	8.0-28.5	1.9-70.0
Whee Print26 (34)Other White6 (4.0)Pakistani9 (20.9)The Asian background3 (7.0)Diagoosis at admission12 (24.5)SIRS sepsis/shock12 (24.5)SIRS sepsis/shock2 (24.5)Cardiac arrow6 (0.2)Elective sargical4 (8.2)Energery Stagical4 (8.2)Taruma3 (6.1)Other7 (4.3)Prescriving Bines16 (3.6)Near16 (3.6)Near16 (3.6)Nearmscular2 (4.1)Other7 (14.3)Scizmes3 (6.1)Other2 (4.2)Scizmes3 (6.1)Other10 (2.2)Ventilated (days)43 (87.7)Scizmes0Other0-2Ustripted (days)43 (87.7)Fights110Other0-11Other0-11Other12 (2.2)Fights111Ibid IndianaFights113Ibid IndianaIbid Indiana <td>Ethnicity</td> <td>43 available</td> <td></td> <td></td> <td></td>	Ethnicity	43 available			
Oder Mine6(40)Palsisami9(209)Other Asian background3(7.0)Diagnost at dmission12(24.5)Paemonia12(24.5)Cardiae arros10(0.2)Elective arroysingla4(8.2)Elective arroysingla4(8.2)Taruma3(6.1)Setzures2(4.3)Other A (14.3)1Setzures4(4.3)Other A (14.3)1Setzures3(6.1)Unama6(1.4)Other A (14.3)1Setzures3(6.1)Other A (14.3)1Setzures3(6.1)Other A (14.3)1Other A (14.3)	White British	25 (58.1)			
Palani basima9 (20.9)Other Asian background3 (70.7)Diagnois it admissionPennovini12 (24.5)SIRS sepsis/shock2 (24.5)Cardia arres6 (0.0.2)Elective sangial4 (8.2)Energency Sargical4 (8.2)I'mura6.6.1)Sizruss2 (4.1)Other7 (4.3)Seizures7 (4.3)Neuromusular6 (6.1)Genetic7 (14.3)Startures3 (6.1)Other16 (32.6)Startures7 (4.3)Startures3 (6.1)Other2 (4.2)Other2 (4.2)Startures3 (6.1)Startures3 (6.1)Other2 (4.2)Startures3 (6.1)Other2 (4.2)Startures3 (6.1)Data5 (1.2)Startures3 (6.1)Civer10Other10 (2.1)Elective10Other10 (2.1)Elective11Iphish1Iphish12 (2.1)Fight Startures11Iphish12 (2.1)Iphish12 (2.1)Iphish<	Other White	6 (14.0)			
Oder Asian background9 (2 (7)Diagnotics at admissionPherumoria12 (24.5)SRSsepsis/shock2 (24.5)Cardia carest5 (10.2)Elective surgical4 (8.2)Thuma3 (6.1)Seizures2 (4.1)Seizures7 (4.3)Order7 (4.3)None16 (2.2 (1.2))Gencia7 (14.3)Seizures3 (6.1)Seizures3 (6.1)Seizures3 (6.1)Gencia7 (14.3)Order2 (4.2)Order3 (87.7)Seizures3 (6.1)Other1 (2.2)Vertilat (days)3 (87.7)Seizures1 (2.2)Intrope score4 (2.2)Highest0Intrope score1 (2.2)Highest1 (2.1)PEJO score1 (2.2)Highest1 (3.1)Intrope score1 (3.2)Highest1 (3.1)PEJO score1 (2.2)Highest1 (3.1)PEJO score1 (3.2)Highest1 (3.1)PEIO score1 (3.2)PEIO score1 (3.2)Pitores score1 (3.2) <td< td=""><td>Pakistani</td><td>9 (20.9)</td><td></td><td></td><td></td></td<>	Pakistani	9 (20.9)			
<table-container>DisponsibilityPremoving12 (24.5)SIRDS spissionola5 (0.2)Cardiac arrest6 (0.2)Energency Surgial4 (8.2)Truuma3 (6.1)Seiznes2 (4.1)Other7 (4.3)Pre-existing illness16 (32.6)Nono16 (32.6)Nono16 (32.6)Seiznes2 (4.1)Other2 (4.1)Other2 (4.1)Vertraited (days)16 (32.6)Nono16 (32.6)Seiznes2 (4.1)Other2 (4.1)Other2 (4.1)Other2 (4.1)Vertraited (days)3 (87.7)Seiznes3 (4.1)Other10Other10Other9Other9Other10Other10Other11Intotope sore4Ighest1Ighest<</table-container>	Other Asian background	3 (7.0)			
Pacamonia12 (24.5)KTRS12 (24.5)Cardia arros12 (24.5)Cardia arros4 (8.2)Electivo surgical4 (8.2)Innuma6 (6.1)Seizures2 (4.1)Other7 (1.3)Pre-cxisting illens16 (32.6)Normonuscular2 (4.1)Normonuscular2 (4.1)Genetic7 (1.4)Seizures3 (6.1)Other12 (4.2)Norumonuscular2 (4.2)Other2 (4.2)Other2 (4.2)Other3 (6.7)Other3 (6.7)Ventland (days)3 (6.7)Seizures10Other12Norumoscular10Other0.0-0Other10Other0.0-0Death10Other10Death0.0-0Interpretor1Mores1Juest10Other1.0-21Other1.0-21Death1.0-21Pieldes1.0Other1.0-21Unit output (mL Maght)1.0Interpretor1.0Interpretor1.0Pieldes0.1Interpretor1.0Interpretor1.0Interpretor1.0Interpretor1.0Interpretor1.0Interpretor1.0Interpretor1.0Interpretor1.0Interpretor1.0 <t< td=""><td>Diagnosis at admission</td><td></td><td></td><td></td><td></td></t<>	Diagnosis at admission				
SIRS/sepsishock12 (24.5)Cardia arest5 (0.2)Cardia arest5 (0.2)Elective surgial4 (8.2)Tununa3 (6.1)Scizures2 (4.1)Other7 (14.3)Pre-scisting illness1 (6.1)Neuromuscular2 (4.1)Genetic7 (14.3)Seizures3 (6.1)Other2 (42.8)Ventilated (days)3 (8.7)Seizures3 (8.7)Other2 (42.8)Ventilated (days)3 (8.7)Seizures10Other9.0Overst10.2Instrope score44Highest1 (3.0)PicLOP score1Highest1 (3.0)PicLOP score1 (3.0)PicLOP score <td>Pneumonia</td> <td>12 (24.5)</td> <td></td> <td></td> <td></td>	Pneumonia	12 (24.5)			
Cardia carrest5 (10.2)Elerrique vagical4 (8.2)Emergency Surgical4 (8.2)Trauma3 (6.1)Seizures2 (4.1)Other7 (14.3)Pre-scisting illues16 (32.6)Neuromuscular2 (4.1)Genetic7 (14.3)Seizures3 (6.1)Other2 (4.2)Other2 (4.2)Other2 (4.2)Other3 (8.7)Seizures3 (6.1)Other2 (4.2)Other2 (4.2)Other2 (4.2)Other1 (2.2)EVVH1 (2.2)Instress1Highest1Instress1Highest1Instress1PELOD score1Instress1 </td <td>SIRS/sepsis/shock</td> <td>12 (24.5)</td> <td></td> <td></td> <td></td>	SIRS/sepsis/shock	12 (24.5)			
Icerity surgical4 (8.2)increageory Surgical4 (8.2)increageory Surgical4 (8.2)increageory Surgical3 (6.1)Scizures O7 (14.3)Vre-existing illness16 (32.6)Vere-issing illness16 (32.6)Seizures O2 (4.1)Genetic7 (14.3)Seizures O3 (6.1)Seizures O3 (6.1)Other2 1 (42.8)Vertilated (days)43 (87.7)Seizures O44CVH12 (20.2)Nortpe score44Highest0Lowers0PELOD score44Highest10Lowers11Idoversone11 (22.9)Petersone11 (22.9)Idoversone11 (22.9)Idoversone11 (22.9)Intrope score11 (22.9)Idoversone11 (22.9)Idoversone11 (22.9)Idoversone11 (22.9)Idoversone11 (22.9)Idoversone11 (22.9)Idoversone11 (22.9)Idoversone11 (23.9)Idoversone11 (23.9)<	Cardiac arrest	5 (10.2)			
Intergency Surgical4 (8.2)Turuma3 (6.1)Seizures2 (4.1)Other1 (32.6)Neuromuscular6 (32.6)Seizures3 (6.1)Other2 (4.1)Genetic7 (14.3)Seizures3 (6.1)Other2 (4.2)Ventilated (days)3 (6.7)Other1 (32.6)Ventilated (days)4 (8.7)Death5 (10.2)Interpes core6 (10.2)Highest0Lowest0Dosore44PELOD score1Highest1Lowest1Dosore11 (2.2)Vice output (mL/kg/n)18 (37.5)Fresh focze plasma11 (2.2)Oyoprecipitate1 (2.0)Piteles3 (6.3)Virice output (mL/kg/n)3 (6.3)Vice output (mL/kg/n)3 (6.3)Negrossioks9 (18.4)Negrossioks9 (18.4)Negrossioks9 (18.4)Negrossioks9 (18.4)Negrossiokal anti-inflammatory drugs8 (16.5)	Elective surgical	4 (8.2)			
Tauma3 (6.1)Sizuros2 (4.1)Other7 (14.3)Pre-xisting illness16 (32.6)Nuromuscular2 (4.1)Genetic7 (14.3)Sizuros3 (6.1)Other2 (42.8)Ventilated (days)43 (87.7)Death5 (10.2)CVVH1 (2)Inotres score44Highest0Lowest0PEDOSore44Highest13Inotrop score14Highest13Inotrop score11PEdodo poladicies12-21Petodo poladicies13PELO score11Highest13Inotrop score12Highest13Inotrop score10PELO score12Highest13Inotrop score10Highest10.0Pictores plasma11 (22.9)Cryoprecipitate12.0)Pitelets36.3)Urine output (mL/kgh)12.0)Pitelets0.5Aminoglycosides12.0Aminoglycosides12.0Ficoplanin48.2)Ficoplanin48.2)Ficoplanin48.2)Ficoplanin48.2)Ficoplanin24.40.0)Nonstervicki anti-inflammatory drugs816.3)	Emergency Surgical	4 (8.2)			
Seizures 2 (4.) Other 7 (14.3) Pre-existing illnes I None 6 (32.6) I Neuromuscular 2 (4.1) I Genetic 7 (14.3) I I Seizures 3 (6.1) I I Other 1 (42.8) I I Ventilated (days) 43 (87.7) 5 3-9 2-14 Death 1 (20.2) I I I Intotry score 44 I I I ELOD score 44 I I I I Intotry score 44 I I I I I Intoty score 1 I	Trauma	3 (6.1)			
Oher7 (14.3)Pre-existing illness16 (3.6)Neuronuscular2 (4.1)Genetic7 (14.3)Seizures3 (6.1)Other2 (142.8)Ventilated (days)43 (87.7)5Death5 (10.2)CVVH1 (2)Intorpe score44Highest00-9Lowest00-13PELOD score44Highest131-21Body Opercipitate110-11Body Opercipitate12.2)Presh finzen plasma11 (2.2)Cyprecipitate12.3)Platelts36.3)Ventilated, functional plasma11 (2.2)Cyprecipitate12.4)Platelts0.5Neweto0.5Ventional plasma31 (67.3)Animoglycosides918.4)Piptrotoxic medication33 (67.3)Animoglycoside918.4)Nonservoidel anti-inflammatory drugs816.3)	Seizures	2 (4.1)			
Pre-existing illness None 16 (32.6) None 16 (32.6) None 2 (4.1) Genetic 3 (6.1) Other 2 (14.3) Seizures 3 (6.1) Other 2 (14.3) Ventlated (days) 43 (87.7) 5 3–9 2–14 Death 10.2) 2 2 2 CVVH 10.2) - 2 1 2 Inotrope score 44 - - 1 0 0 1	Other	7 (14.3)			
None 16 (32.6) Neuromuscular 2 (4.1) Genetic 7 (14.3) Seizures 3 (6.1) Other 21 (42.8) Ventilated (days) 43 (87.7) 5 3-9 2-14 Death 5 (10.2) - - - - CVVH 1 (2) -	Pre-existing illness				
Neuronuscular 2 (4.) Genetic 7 (14.3) Scizures 3 (6.1) Other 2 (14.2.8) Ventilated (days) 3 (87.7) 5 3-9 2-14 Death 5 (10.2) - - - - CVVH 1 (2) -<	None	16 (32.6)			
Genetic 7 (14.3) Scizures 3 (6.1) Other 21 (42.8) Ventilated (days) 43 (87.7) 5 3-9 2-14 Death 5 (10.2) - 2 - CVVH 1 (2) -	Neuromuscular	2 (4.1)			
Seizures 3 (6.) Other 21 (42.8) Ventilated (days) 43 (87.7) 5 3–9 2–14 Deah 5 (10.2) -<	Genetic	7 (14.3)			
Other 21 (42.8) Ventilated (days) 5 3-9 2-14 Death 5 (10.2) - - CVVH 1(2) - <	Seizures	3 (6.1)			
Ventilated (days) 43 (87,) 5 3-9 2-14 Death 5 (10.2) \cdot	Other	21 (42.8)			
Death 5 (0.2) CVVH 1(2) Inotrope score 44 Highest 0 0-9 0-61 Lowest 0 0 0-0 0-13 PELOD score 44 1 11-21 0-41 Lowest 1 0-11 0-20 0 PELOD score 44 1 0-11 0-20 Blood products 1 0-11 0-20 Blood products 1 0-11 0-20 Vhole blood 18 (37.5)	Ventilated (days)	43 (87.7)	5	3–9	2-14
CVVH 10 Inotrope score 44 Highest 0 0-9 0-61 Lowest 0 0-0 0-13 PELOD score 44 1 0-01 0-13 PELOD score 44 11-21 0-41 0-41 Lowest 1 0-11 0-20 0-20 Blood products 1 0-11 0-20 Fresh frozen plasma 11 (22.9)	Death	5 (10.2)			
Inotrope score 44 Highest 0 0-99 0-61 Lowest 0 0-00 0-13 PELOD score 44 1 0-11 0-41 Lowest 13 11-21 0-41 Lowest 1 0-11 0-20 Blood products 1 0-11 0-20 Blood products 1 0-11 0-20 Blood products 1 0-11 0-20 Cryoprecipitate 12(2.9)	CVVH	1 (2)			
Highest 0 0-9 0-61 Lowest 0 0-0 0-13 PELOD score 44 1 0-11 0-41 Lowest 13 11-21 0-41 Lowest 1 0-11 0-20 Blood products 1 0-11 0-20 Khole blood 18 (37.5)	Inotrope score	44			
Lowest 0 0-0 0-13 PELOD score 44	Highest		0	0–9	0-61
PELOD score 44 Highest 13 11–21 0-41 Lowest 1 0–10 0-20 Blood products 1 0–11 0–20 Blood products 1 0.20 0.20 Fresh frozen plasma 11 (22.9) - - - - Platelets 3 (6.3) -	Lowest		0	0–0	0-13
Highest 13 11–21 0-41 Lowest 1 0–11 0–20 Blood products 1 1 0–20 Whole blood 18 (37.5) - - Fresh frozen plasma 11 (22.9) - - Cryoprecipitate 1 (2.0) - - Platelets 3 (6.3) - - Urine output (mL/kg/h) - 7.1 5.4–11.1 0.9–15.3 Lowest 0.5 0.4–0.7 0.0–1.4 Nephrotoxic medication 33 (67.3) - - Yancomycin 1 (2.0) - - - Fuosenide 9 (18.4) - - - Vancomycin 1 (2.0) - - - - Fuosenide 24 (49.0) - - - - Nonsteroidal anti-inflammatory drugs 8 (16.3) - - - -	PELOD score	44			
Lowest 1 0-11 0-20 Blood products 1 0.01 0-20 Whole blood 18 (37.5) 1 1 Fresh frozen plasma 11 (22.9) 1 1 Cryoprecipitate 1 (2.0) 1 1 Platelets 3 (6.3) 1 1 Urine output (mL/kg/h) 7.1 5.4-11.1 0.9-15.3 Lowest 0.5 0.4-0.7 0.0-1.4 Nephrotoxic medication 33 (67.3) 1 1 Vancomycin 1 (2.0) 1 1 1 Furosemide 9 (18.4) 1 1 1 Nonsteroidal anti-inflammatory drugs 8 (16.3) 1 1 1	Highest		13	11–21	0-41
Blood products 18 (37.5) Yende blood 18 (37.5) Fresh frozen plasma 11 (22.9) Cryoprecipitate 1 (2.0) Platelets 3 (6.3) Urine output (mL/kg/h) 7.1 5.4–11.1 0.9–15.3 Lowest 0.5 0.4–0.7 0.0–1.4 Nephrotoxic medication 33 (67.3) 1 1 Yancomycin 1 (2.0) 1 1 Teicoplanin 4 (8.2) 1 1 Furosemide 24 (49.0) 1 1 Nonsteroidal anti-inflammatory drugs 8 (16.3) 1 1	Lowest		1	0-11	0–20
Whole blood 18 (37.5) Fresh frozen plasma 11 (22.9) Cryoprecipitate 1 (2.0) Platelets 3 (6.3) Urine output (mL/kg/h) 7.1 5.4–11.1 0.9–15.3 Lowest 0.5 0.4–0.7 0.0–1.4 Nephrotoxic medication 33 (67.3) 0.4–0.7 0.0–1.4 Vancomycin 1 (2.0) 1 (2.0) 1 (2.0) Teicoplanin 4 (8.2) 4 (8.2) 1 (2.0) Furosemide 24 (49.0) 8 (16.3) 1 (2.0)	Blood products				
Fresh frozen plasma 11 (22.9) Cryoprecipitate 1 (2.0) Platelets 3 (6.3) Urine output (mL/kg/h) 7.1 5.4–11.1 0.9–15.3 Lowest 0.5 0.4–0.7 0.0–1.4 Nephrotoxic medication 33 (67.3) 4.07 0.0–1.4 Vancomycin 1 (2.0) 1 (2.0) 1 (2.0) Teicoplanin 4 (8.2) 4 (8.2) 1 (2.0) Furosemide 24 (49.0) 8 (16.3) 1 (2.0)	Whole blood	18 (37.5)			
Cryoprecipitate 1 (2.0) Platelets 3 (6.3) Urine output (mL/kg/h) 7.1 5.4–11.1 0.9–15.3 Lowest 0.5 0.4–0.7 0.0–1.4 Nephrotoxic medication 33 (67.3) 0.4–0.7 0.0–1.4 Nephrotoxic medication 1 (2.0) 1 (2.0) 1 (2.0) Teicoplanin 4 (8.2) 4 (8.2) 1 (2.0) Furosemide 24 (49.0) 8 (16.3) 1 (2.0)	Fresh frozen plasma	11 (22.9)			
Platelets 3 (6.3) Urine output (mL/kg/h) 7.1 5.4–11.1 0.9–15.3 Highest 7.1 5.4–11.1 0.9–15.3 Lowest 0.5 0.4–0.7 0.0–1.4 Nephrotoxic medication 33 (67.3) 9 (18.4) 1 (2.0) 1 (2.0) Yancomycin 1 (2.0) 1 (8.2) 1 (49.0) 1 (49.0) Nonsteroidal anti-inflammatory drugs 8 (16.3) 1 (1.3) 1 (1.3)	Cryoprecipitate	1 (2.0)			
Urine output (mL/kg/h) 7.1 5.4–11.1 0.9–15.3 Highest 0.5 0.4–0.7 0.0–1.4 Nephrotoxic medication 33 (67.3) 0.4–0.7 0.0–1.4 Nephrotoxic medication 33 (67.3) 1(2.0) 1(2.0) 1(2.0) Teicoplanin 4 (8.2) 4(8.2) 1 1(2.0) Furosemide 24 (49.0) 8 (16.3) 1	Platelets	3 (6.3)			
Highest 7.1 5.4–11.1 0.9–15.3 Lowest 0.5 0.4–0.7 0.0–1.4 Nephrotoxic medication 33 (67.3) 0.4–0.7 0.0–1.4 Aminoglycosides 9 (18.4) 1 (2.0) 1 1 (2.0) Teicoplanin 4 (8.2) 4 (49.0) 1 1 Nonsteroidal anti-inflammatory drugs 8 (16.3) 8 (16.3) 1 1	Urine output (mL/kg/h)				
Lowest 0.5 0.4–0.7 0.0–1.4 Nephrotoxic medication 33 (67.3) 0.4–0.7 0.0–1.4 Aminoglycosides 9 (18.4) 12.0) 12.0) Teicoplanin 4 (8.2) 12.0 14.0 Furosemide 24 (49.0) 14.0 14.0 Nonsteroidal anti-inflammatory drugs 8 (16.3) 16.3 16.3	Highest		7.1	5.4–11.1	0.9–15.3
Nephrotoxic medication33 (67.3)Aminoglycosides9 (18.4)Vancomycin1 (2.0)Teicoplanin4 (8.2)Furosemide24 (49.0)Nonsteroidal anti-inflammatory drugs8 (16.3)	Lowest		0.5	0.4–0.7	0.0–1.4
Aminoglycosides9 (18.4)Vancomycin1 (2.0)Teicoplanin4 (8.2)Furosemide24 (49.0)Nonsteroidal anti-inflammatory drugs8 (16.3)	Nephrotoxic medication	33 (67.3)			
Vancomycin1 (2.0)Teicoplanin4 (8.2)Furosemide24 (49.0)Nonsteroidal anti-inflammatory drugs8 (16.3)	Aminoglycosides	9 (18.4)			
Teicoplanin4 (8.2)Furosemide24 (49.0)Nonsteroidal anti-inflammatory drugs8 (16.3)	Vancomycin	1 (2.0)			
Furosemide24 (49.0)Nonsteroidal anti-inflammatory drugs8 (16.3)	Teicoplanin	4 (8.2)			
Nonsteroidal anti-inflammatory drugs 8 (16.3)	Furosemide	24 (49.0)			
	Nonsteroidal anti-inflammatory drugs	8 (16.3)			

CVVH, Continuous veno-venous hemofiltration, PELOD, Paediatric Logistic Organ Dysfunction



Fig. 2 Comparison of pre-admission and pre-discharge estimated creatinine clearance (*eCCl*) values for patients enrolled in the study. *Red line* Presumed eCCl value of 120 mL/min/1.73 m^2 used in the paediatric RIFLE classification for acute kidney injury

observed for Cys-C (r=-0.77, p<0.0001), a weak correlation was observed for pNGAL (r=-0.14, p=0.043) and uNGAL (r=-0.13, p=0.045), and there was no significant correlation with coincident eCCl and the urinary biomarker KIM-1 (r=-0.076, p=0.26).

Biomarkers elevated in AKI

We investigated whether biomarker levels changed according to AKI severity. For the three groups we considered (no AKI, pRIFLE R, pRIFLE I/F), we found that pNGAL (p=0.027) and uNGAL (p=0.0079) levels were significantly higher in periods of pRIFLE I/F (Fig. 4) and that Cys-C levels were significantly higher in periods of both pRIFLE R and pRIFLE I/F (p<0.0001). This result suggests that the biomarker levels of Cys-C, pNGAL and uNGAL may aid the diagnosis of AKI.

Biomarker sensitivity and specificity

To identify which of the biomarkers provided the highest sensitivity and specificity, we performed an ROC analysis using both 'pRIFLE R or worse', and 'pRIFLE I or worse' to define AKI. All biomarkers displayed superior predictive power for 'pRIFLE I or worse' compared to 'pRIFLE R or worse'. The best performing biomarkers were Cys-C and pNGAL (Fig. 5). We also considered the variation of Cys-C with age. It has been reported that infants under the age of 18 months have a higher mean Cys-C value than older children [26]. To determine if this pattern held true in our patient cohort, we compared median Cys-C values of patients not experiencing AKI under 18 months old to those older than 18 months and found no significant difference (≤18 months 0.75 mg/L, \geq 18 months 0.78 mg/L; p=0.66). We additionally examined whether a correlation between fluid status and biomarker levels existed. No significant correlation was observed for Cys-C, pNGAL or uNGAL, although a weak correlation was observed for KIM-1 (ESM Fig. 2).



b pNGAL 150 eCCI eCCI (mL/min/1.73m²) pNGAL 100-JGAL (ng/mL 50 5 r Þ 6 ٩ ę. Day post admission d KIM 1 150 10000 eCCI AKI KIM-1 eCCI (mL/min/1.73m²) 8000 KIM 1 (pg/mgCr) 100 6000 1000 50 2000 5 6 r ზ Þ Day post admission

Fig. 3 Biomarker profiles plots for a patient with acute kidney injury (AKI) according to the most severe pRIFLE stratum reached by the patient during PICU admission (pRFILEmax). This patient reached the pRIFLEmax Injury (I) stratum at day 7 after admission to the PICU. *Black filled circles/lines* eCC1 (mL/min/1.73 m²), *red filled squares/lines*

biomarker levels. **a** cystatin-C (*Cys-C*; mg/L), **b** plasma neutrophil gelatinase-associated lipocalin (*pNGAL*; ng/mL), **c** urinary NGAL (*uNGAL*; ng/mg Cr), **d** kidney injury molecule-1 (*KIM-1*; pg/mg Cr). Note that the period of AKI is given on the top right of each plot. As eCCl declines over time, the level of each of biomarker increases



Fig. 4 Box and whisker graph showing biomarker levels according to pRFILE stratum. **a** Cys-C levels were significantly higher during periods of pRIFLE Risk (*R*) compared to no acute kidney injury (AKI) (*No AKI*), and during periods of pRIFLE Injury or Failure (*I or F*) compared to pRIFLE R (p < 0.05). **b**, **c** pNGAL (**b**; p = 0.027) and uNGAL (**c**; p =

The utility of pNGAL in AKI associated with sepsis

It has previously been reported that Cys-C and uNGAL levels are not altered by sepsis, whereas pNGAL levels rise in sepsis and cannot reliably discriminate AKI from no AKI in the septic state [27]. As 24/49 (49.0 %) of our patients were admitted to the PICU with either sepsis or pneumonia, we examined whether pNGAL was a valid AKI biomarker in sepsis in our patient cohort. For patients admitted to PICU with either sepsis or pneumonia, we compared biomarker levels during periods of no AKI to periods of AKI using an AKI definition of pRIFLE R or worse (Fig. 6). Whereas Cys-C retained its ability to discriminate no AKI from AKI (p < 0.0001), there was no significant difference in pNGAL levels between no AKI and AKI periods in patients admitted with sepsis or pneumonia (p = 0.97). We also performed an ROC analysis using median biomarker values for patients admitted to the PICU with either sepsis or pneumonia, using pRIFLE R as a cut-off between no AKI and AKI. Again, Cys-C retained its utility as

0.0079) levels were significantly higher in periods of pRIFLE I or F compared to no AKI. **d** No significant difference in KIM-1 levels were observed (p = 0.2108). In all plots, the box extends from the 25th to 75th data percentiles; *line in the middle of box* is plotted at the median, *box plot whiskers* denote 5th and 95th data percentiles

an AKI biomarker in this patient group (AUC 0.86, p=0.002), while pNGAL performed poorly (AUC 0.54, p=0.71). Thus, our data support the previous data indicating that pNGAL is not a reliable biomarker for AKI associated with sepsis.

Identification of biomarker cut-off levels

By examining biomarker levels in periods of no AKI and AKI (Fig. 4) and the ROC analysis (Fig. 5), we concluded that Cys-C and pNGAL were the best performing biomarkers to diagnose AKI in our study group. We proceeded to identify biomarker cut-off values, including Cys-C and pNGAL for patients without sepsis or pneumonia, and Cys-C alone for patients with sepsis or pneumonia. Proposed biomarker cut-off levels were set according to the sensitivities and specificities provided by the ROC analyses. From these analyses we identified a Cys-C value of >0.91 mg/L (75 % sensitivity, 82 % specificity) and a pNGAL value of >258 ng/mL (88 % sensitivity, 62 % specificity) as cut-off levels for AKI.



Fig. 5 Receiver operating characteristic (ROC) curve analysis was performed to evaluate the ability of Cys-C (**a**), pNGAL (**b**), uNGAL (**c**) and KIM-1 (**d**) to diagnose acute kidney injury (AKI). *Green lines* ROC curves showing biomarker sensitivity and specificity if an AKI definition

of pRIFLE R or worse is used, *red lines* ROC curves illustrating biomarker performance if an AKI definition of pRFILE I or worse is used. e Area under the curve (*AUC*) values. *CI* Confidence interval





Fig. 6 Biomarker levels in periods of no acute kidney injury (AKI) compared to periods of AKI in patients admitted to PICU with sepsis or pneumonia. Cys-C (a), pNGAL (b), uNGAL (c) and KIM-1 (d) in

periods of AKI (defined by pRIFLE R or worse) in this patient group. There was no significant difference in pNGAL levels during AKI (*p* value 0.97). *Red lines* Mean biomarker values. ***p<0.0001

A biomarker panel improves specificity for AKI

To test the hypothesis that biomarker specificity may be improved by introducing a requirement for abnormal Cys-C and pNGAL values to be recorded at the same time, patients without sepsis or pneumonia were split into three groups (Fig. 1b). pNGAL was not considered here as our results had already shown that it is not a reliable AKI marker in patients with sepsis or pneumonia. Group 1 contained patients not experiencing an AKI episode during PICU admission, Group 2 contained patients experiencing AKI on PICU admission (to test the hypothesis in patients with established AKI) and Group 3 consisted of patients with no AKI evident on PICU admission but who subsequently experienced an AKI episode during PICU admission (to test the hypothesis in patients prior to AKI onset). For this analysis, patients with pRIFLE R or worse were considered to have AKI. We found that the combination of Cys-C and pNGAL improved the specificity of the test [92.9 %, compared with the use of either Cys-C or pNGAL alone (85.7 % and 57.1 % respectively)] (Table 2). For patients in Group 2 (established AKI), this improved specificity came without a loss of sensitivity (compared to either test in isolation). However, contemporaneous combination of the two biomarkers in Group 3 (prior to AKI) reduced sensitivity to only 20 %. One possible explanation is that Cys-C and pNGAL peak at different times prior to an episode of AKI. We therefore proceeded to examine the temporal profiling of these biomarkers.

Temporal profiling of plasma biomarkers

We investigated the time course of Cys-C and pNGAL levels in the period prior to AKI onset for the four patients in Group 3 who were admitted to PICU without sepsis or pneumonia. Using the cut-off values of >0.91 mg/L for Cys-C and >258 ng/mL for pNGAL, an abnormal pNGAL value was

 Table 2
 Assessment of the change in sensitivity and specificity of acute kidney injury biomarkers using contemporaneous measurements in patients admitted with a diagnosis other than sepsis or pneumonia compared to single biomarkers in isolation

Biomarker	Sensitivity (%)	Specificity (%)
Cys-C alone (in Group 2)	100	85.7
pNGAL alone (in Group 2)	100	57.1
C+P (in Group 2)	100	92.9
Cys-C alone (in Group 3)	60	85.7
pNGAL alone (in Group 3)	80	57.1
C+P (in Group 3)	20	92.9

C+P, Contemporaneous abnormal cystatin C (Cys-C) and plasma human neutrophil gelatinase-associated lipocalin (pNGAL)

For definition of groups, see Fig. 1b and section A biomarker panel improves specificity for acute kidney injury (AKI)

recorded in three of these patients prior to AKI onset, while none of the patients had an abnormal Cys-C reading prior to AKI onset. Additionally, the highest recorded pNGAL level in a given patient's biomarker profile occurred prior to AKI onset in all four patients, compared to two of the four patients for Cys-C. In this limited data set, pNGAL levels tended to peak earlier than Cys-C levels and were often declining by the time the Cys-C levels began to rise.

Temporal profiling of urinary biomarkers

The urinary biomarkers uNGAL and KIM-1 displayed a poor ability to diagnose AKI in the general patient group (Fig. 5). However, in an exploratory analysis, we examined the possibility that these biomarkers may have utility in predicting future AKI using data from all patients developing AKI after admission to PICU. We identified urinary biomarker values from six patients (pRIFLE R or worse) in the 24 h prior to an AKI episode and compared these to median values in the 24 h post-AKI. Five of these six patients had lower uNGAL levels in the 24 h after AKI diagnosis, while five displayed higher KIM-1 levels in the 24 h after AKI diagnosis. The possibility that uNGAL may peak before the diagnosis of AKI using pRIFLE criteria and thus act as an early marker of AKI could be explored in a future, appropriately powered study.

Patients with AKI and normal eCCl

Three patients in the study reached pRIFLE AKI criteria on the basis of low urine output alone (i.e. had normal eCCl). Biomarker profile plots are provided in ESM Figs. 3–5. No pNGAL plot is provided in ESM Fig. 5 since this patient was admitted with sepsis. The remaining two patients both had pNGAL readings which exceeded our proposed pNGAL cut-off value of 258 ng/mL prior to AKI diagnosis. All three patients recorded their highest uNGAL level prior to AKI diagnosis. Again, this result suggests that pNGAL and uNGAL may be earlier and more sensitive markers of AKI than SCr.

Discussion

In this investigation, we tested a panel of plasma and urinary biomarkers to diagnose AKI in a general PICU setting. We have demonstrated that recruitment and sample collection is feasible using a retrospective consent model in a mixed patient cohort. We provide evidence that Cys-C and pNGAL are useful biomarkers for established AKI without sepsis and that Cys-C remains a valid biomarker for established AKI with sepsis. Contemporaneous readings of Cys-C and pNGAL improve the specificity without affecting the sensitivity in diagnosing established AKI without sepsis compared to either biomarker alone, and we provide preliminary data that pNGAL and uNGAL may be useful early markers of AKI.

In our patient cohort, Cys-C levels did not provide earlier warning of an AKI episode than SCr. However, Cys-C measurements may be of practical benefit in diagnosing AKI when no baseline SCr level is available for a patient. Cys-C levels are not dependent on muscle mass, and it is therefore possible to avoid one of the major pitfalls of an SCr-based AKI diagnosis [28]. Our ROC analysis suggests that a Cys-C cut-off value of 0.91 mg/L may be useful to identify AKI.

In our patient group, both Cys-C and pNGAL performed well individually for diagnosing established AKI (without sepsis), and we suggest a cut-off value of 258 ng/mL for pNGAL. However, the specificity of the biomarkers was improved by using combined contemporaneous measurements. Indeed, a biomarker panel may ultimately improve our current ability to diagnose AKI based on eCCl.

Several studies to date have used an eCCl of 120 mL/min/ 1.73 m^2 as a presumed baseline value for children without a documented pre-admission eCCl. We found that preadmission eCCl values were only available in 8.2 % of our patient cohort; this may be more of an issue in paediatric practice compared to adult practice, since children are more likely to be healthy prior to their hospital admissions. As a consequence, a majority of children in our study were presumed to have a baseline eCCl of 120 mL/min/1.73 m². Previous studies have also noted a low proportion (24 %) of paediatric emergency admissions having a pre-recorded eCCl value [18] and also a high mean baseline eCCl of 154 mL/min/ 1.73 m^2 for a mixed cohort of children admitted to an ICU [4]. Our data suggest that an eCCl value of 120 mL/min/1.73 m² underestimates the actual baseline renal function for a majority of children and may lead to underdiagnosis of AKI.

In summary, we suggest that Cys-C has immediate utility for confirming a diagnosis of AKI in children admitted to intensive care. pNGAL and uNGAL may peak before the onset of AKI and therefore have the potential to predict episodes of AKI, although there needs to be caution with the use of pNGAL in sepsis. We propose that future AKI biomarker studies in a general PICU setting should differentiate patients admitted with sepsis from those admitted for other indications. Such a study would be the next step towards developing a biomarker panel, which in combination with risk stratification, could identify those children who need to be protected from secondary renal injury during their inpatient admission.

Acknowledgements We acknowledge technical support from Mr. Ian Read, Department of Renal Medicine, Central Manchester University Hospitals NHS Foundation Trust (CMFT), Anne Shenton (CMFT) and Michelle Hurst (CMFT). Recruitment support was provided by Mrs. Maria McDonald and Mr. Philip Hudnot, Paediatric Intensive Care Unit, Royal Manchester Children's Hospital. We received helpful advice regarding analyses from Cyril Clarke and Richard Mills, ICON plc. Roche Ltd. provided reagents, calibrators and controls for the Cys-C assay.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

- Askenazi DJ, Feig DI, Graham NM, Hui-Stickle S, Goldstein SL (2006) 3–5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int 69:184–189
- Basu RK, Devarajan P, Wong H, Wheeler DS (2011) An update and review of acute kidney injury in pediatrics. Pediatr Crit Care Med 12:339–347
- Askenazi DJ, Ambalavanan N, Goldstein SL (2009) Acute kidney injury in critically ill newborns: what do we know? What do we need to learn? Pediatr Nephrol 24:265–274
- Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL (2007) Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 71:1028–1035
- Moran SM, Myers BD (1985) Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int 27:928–937
- Endre ZH, Pickering JW (2013) Acute kidney injury clinical trial design: old problems, new strategies. Pediatr Nephrol 28:207–217
- Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinaseassociated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534–2543
- Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M (1998) Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273:4135–4142
- Dent CL, Ma Q, Dastrala S, Bennett M, Mitsnefes MM, Barasch J, Devarajan P (2007) Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care 11:R127
- Trachtman H, Christen E, Cnaan A, Patrick J, Mai V, Mishra J, Jain A, Bullington N, Devarajan P, Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial (2006) Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 21:989–994
- Hoffman SB, Massaro AN, Soler-Garcia AA, Perazzo S, Ray PE (2013) A novel urinary biomarker profile to identify acute kidney injury (AKI) in critically ill neonates: a pilot study. Pediatr Nephrol 28:2179–2188
- Du Y, Zappitelli M, Mian A, Bennett M, Ma Q, Devarajan P, Mehta R, Goldstein SL (2011) Urinary biomarkers to detect acute kidney injury in the pediatric emergency center. Pediatr Nephrol 26:267–274
- Hassinger AB, Backer CL, Lane JC, Haymond S, Wang D, Wald EL (2012) Predictive power of serum cystatin C to detect acute kidney injury and pediatric-modified RIFLE class in children undergoing cardiac surgery. Pediatr Crit Care Med 13:435–440
- Askenazi DJ, Koralkar R, Hundley HE, Montesanti A, Parwar P, Sonjara S, Ambalavanan N (2012) Urine biomarkers predict acute kidney injury in newborns. J Pediatr 161(270–275):e271
- McWilliam SJ, Antoine DJ, Sabbisetti V, Turner MA, Farragher T, Bonventre JV, Park BK, Smyth RL, Pirmohamed M (2012) Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS One 7:e43809
- Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, Kim RW, Parikh CR, TRIBE-AKI

Consortium (2011) Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: a prospective multicenter study. Crit Care Med 39:1493–1499

- Washburn KK, Zappitelli M, Arikan AA, Loftis L, Yalavarthy R, Parikh CR, Edelstein CL, Goldstein SL (2008) Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant 23:566–572
- Mian AI, Du Y, Garg HK, Caviness AC, Goldstein SL, Bryan NS (2011) Urinary nitrate might be an early biomarker for pediatric acute kidney injury in the emergency department. Pediatr Res 70: 203–207
- Basu RK, Wang Y, Wong HR, Chawla LS, Wheeler DS, Goldstein SL (2014) Incorporation of biomarkers with the renal angina index for prediction of severe AKI in critically ill children. Clin J Am Soc Nephrol 9:654–662
- Pedersen KR, Ravn HB, Hjortdal VE, Norregaard R, Povlsen JV (2010) Neutrophil gelatinase-associated lipocalin (NGAL): validation of commercially available ELISA. Scand J Clin Lab Invest 70: 374–382
- Chaturvedi S, Farmer T, Kapke GF (2009) Assay validation for KIM-1: human urinary renal dysfunction biomarker. Int J Biol Sci 5:128–134

associated lipocalin using urine. Ann Clin Biochem 50:236–244
23. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637

22.

- Choi SC (1977) Tests of equality of dependent correlation coefficients. Biometrika 64:645–647
- Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36
- Fischbach M, Graff V, Terzic J, Bergere V, Oudet M, Hamel G (2002) Impact of age on reference values for serum concentration of cystatin C in children. Pediatr Nephrol 17:104–106
- Di Nardo M, Ficarella A, Ricci Z, Luciano R, Stoppa F, Picardo S, Picca S, Muraca M, Cogo P (2013) Impact of severe sepsis on serum and urinary biomarkers of acute kidney injury in critically ill children: an observational study. Blood Purif 35:172–176
- Kandasamy Y, Smith R, Wright IM (2013) Measuring cystatin C to determine renal function in neonates. Pediatr Crit Care Med 14: 318–322